Abstract
The antiepileptic drug valproic acid is a putative human teratogen as suggested by retrospective studies (Robert and Rosa 1983; Lindhout and Meinardi 1984), a number of case reports (reviewed in Tein and McGregor 1985) and prospective investigations (Koch et al. 1983; Jäger-Roman et al. 1986; Nau et al. 1981a). The use of thus drug for seizure control during pregnancy was shown to result in an increased incidence of neural tube defects, in particular spina bifida aperta in addition to numerous other malformations, particularly of the face and the skeletal structures. Clinical doses range between 10–40 mg/kg/day administered as a single daily dose (Rowan et al. 1981) or in divided doses (Gjerloff et al. 1984). The therapeutic range is said to be between 50–100 µg/ml, although peak drug levels may be much higher: Rowan et al. (1981) reported peak levels of 180 µg/ml in a patient treated with a once-a-day dosing regimen. We have recently measured peak levels of 120 and 184µg/ml in two epileptic patients during the first trimester of pregnancy (Jäger-Roman et al. 1986).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aerts RJ, Durston AJ, Moolenaar WH (1985) Cytoplasmic pH and the regulation of the dictyostelium cell cycle. Cell 43:653–657
Brown NA (1987) Teratogenecity of carboxylic acids, distribution studies in whole embryo culture. In: Nau H, Scott WJ (eds) Pharmacokinetics in teratogenesis. CRC press, Boca Raton, Florida (in press)
Brown NA, Holt D, Webb M (1984) The teratogenicity of methoxyacetic acid in the rat. Toxicol Lett 22:93–100
Collins MW, Scott W, Pitter E, Nau H, Wittfoht W (1986) Correlation of teratogenic potency with alteration of intracellular pH by C-8 carboxylic acids. Teratology 33:45C
Danielsson BRG, Ghantous H, Dencker L (1984) Accumulation in murine amniotic fluid of halothane and its metabolites. Acta Pharmacol Toxicol (Copenh) 55:410–417
Eluma FO, Sucheston ME, Hayes TG, Paulson RB (1984) Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD-I mouse fetus. J Craniofac Genet Dev Biol 4:191–210
Fabro S, Shull G, Brown NA (1984) The teratogenicity of trimethadione and dimethadione. Teratogenesis Carcinog Mutagen 2:61–76
Freese E, Levin BC, Pearce R, Sreevalsan T, Kaufman JJ, Koski WS, Semo NM (1979) Correlation between the growth inhibitory effects, partition coefficients and teratogenic effects of lipophilic acids. Teratology 20:413–440
Gjerloff I, Arentsen J, Alving J, Secher BG (1984) Monodose versus 3 daily doses of sodium valproate: a controlled trial. Acta Neurol Scand 69:120–124
Jäger-Roman E, Deichl A, Jakob S, Hartmann AM, Koch S, Rating D, Steldinger R, Nau H, Helge H (1986) Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J Pediatr 108:997–1004
Kao J, Brown NA, Schmid B, Goulding EH, Fabro S (1981) Teratogenicity of valproic acid: in vivo and in vitro investigations. Teratogenesis Carcinog Mutagen 1:367–382
Keberle H, Loustalot P, Mailer RK, Faigle JW, Schmid K (1965) Biochemical effects of drugs in the mammalian conceptus. Ann NY Acad Sci 123:252–265
Koch S, Jäger-Roman E, Rating D. Helge H (1983) Possible teratogenic effect of valproate during pregnancy. J Pediatr 103:1007
Lewandowski C, Klug S, Nau H, Neubert D (1986) Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture. Arch Toxicol 58:239–242
Lindhout D, Meinardi H (1984) Spina bifida and in utero exposure to valproate. Lancet II:396
Löscher W, Nau H (1985) Pharmacological evaluation of various metabolites and analogues of valproic acid. Neuropharmacology 24:427–435
Löscher W, Nau H, Marescaux C, Vergnes M (1984) Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy. Eur J Pharmacol 99:211–218
Mast TJ, Hendrickx AG, Nau H (1985) Teratology and pharmacokinetics of valproic acid in the rhesus monkey. Teratology 31:25A
Mast TJ, Cukierski MA, Nau H, Hendrickx AG (1986) Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model. Toxicology 39:111–119
Moffa AM, White JA, Mackay EG, Frias JL (1984) Valproic acid, zinc and open neural tubes in 9 day-old hamster embryos. Teratology 29:47A
Nau H (1985) Teratogenic valproic acid concentrations: infusion by implanted minipumps vs. conventional injection regimen in the mouse. Toxicol Appl Pharmacol 80:243–250
Nau H (1986a) Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: the parent drug and not one of the metabolites assayed is implicated as teratogen. Fundam Appl Toxicol 6:662–668
Nau H (1986b) Species differences in pharmacokinetics and drug teratogenesis. Environ Health Persp in press
Nau H (1986c) Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse. Teratology 33:21–27
Nau H, Loscher W (1986) Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam Appl Toxicol 6:669–676
Nau H, Scott WJ (1986) Weak acids as teratogens: drug accumulation in the basic milieu of the early mammalian embryo. Nature 323:276–278
Nau H, Rating D, Koch S, Häuser I, Helge H (1981a) Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Ther 219:768–777
Nau H, Wittfoht W, Schäfter H, Jakobs C, Rating D, Helge H (1981b) Valproic acid in several metabolites: quantitative determination in serum urine, breast milk and tissues by gas chromatogra-phy-mass spectrometry using selected ion monitoring. J Chromatogr 226:69–78
Nau H, Zierer R, Spielmann H, Neubert D, Gansau C (1981c) A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci 29:2803–2814
Nau H, Loscher W, Schafer H (1984) Anticonvulsant activity and embryotoxicity of valproic acid. Neurology 34:400–401
Neubert D, Chahoud I (1985) Significance of species and strain differences in pre- and perinatal toxicology. Acta Histochem [Suppl] (Jena) 31:23–35
Ong LL, Schardein JL, Petrere JA, Sakowski R, Jordan H, Humphrey RR, Fitzgerald JE, de la Iglesia F (1983) Teratogenesis of calcium valproate in rats. Fundam Appl Toxicol 3:121–126
Pagano G, Cipollaro M, Corsale G, Esposito A, Ragucci E, Giordano GG (1985) pH-Induced changes in mitotic and developmental patterns in sea urchin embryogenesis. I. Exposure of embryos. Teratogenesis Carcinog Mutagen 5:101–112
Petrere JA, Anderson JA, Sakowski R, Fitzgerald JE, de la Iglesia FA (1986) Teratogenesis of calcium valproate in rabbits. Teratology 34:263–269
Ritter EJ, Scott WJ, Randall JL, Ritter JM (1985) Teratogenicity of dimethoxyethyl phthalate and its metabolites methoxyethanol and methoxyacetic acid in the rat. Teratology 32:25–31
Robert R, Rosa F (1983) Valproate birth defects. Lancet II:1142
Rowan AJ, Overweg J, Meijer JWA (1981) Monodose therapy with valproic acid: 24 h telemetric EEG and serum level studies. In: Dam M, Gram L, Penry JK (eds) Advances in epileptology. Raven, New York, pp 533–539
Scott WJ, Nau H (1985) Weak acids as human teratogens: accumulation in the young mammalian embryo. Teratology 31:25A
Scott WJ, Duggan CA, Schreiner CM, Collins MD, Nau H (1986) Intracellular pH of rodent embryos and its association with teratogenic response. In: Welsch F (ed) Approaches to evaluate mechanisms in teratogenesis. Hemisphere, Washington
Tagashira E, Nakao K, Urano T, Ishikawa U, Hiramori T, Yanaura S (1981) Correlation of teratogenicity of aspirin to the stagespecific distribution of salicylic acid in rats. Jpn J Pharmacol 31:563–571
Tein I, MacGregor DL (1985) Possible valproate teratogenicity. Arch Neurol 42:291–293
Waddell WJ, Butler TC (1959) Calculation of intracellular pH from the distribution of 5,5-dimethyl-2,4-oxazolidinedione (DMO). Application to skeletal muscle of the dog. J Clin Invest 38:720–729
Willhite CC, Shealy YF (1984) Amelioration of embryotoxicity by structural modification of the terminal group of cancer chemopreventive retinoids. JNCI 72:689–695
Wilson JG (1965) Embryological considerations in teratology. In: Wilson JG, Warkany J (eds) Teratology: principles and techniques. University of Chicago Press, Chicago
Wittfoht W, Duwe K, Kuhnz W, Nau H (1984) Microscale ultrafiltration technique for determining free drug in 50-µl serum samples. Clin Chem 30:878
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag
About this paper
Cite this paper
Nau, H., Scott, W.J. (1987). Teratogenicity of Valproic Acid and Related Substances in the Mouse: Drug Accumulation and pHi in the Embryo During Organogenesis and Structure-Activity Considerations. In: Chambers, C.M., Chambers, P.L., Davies, D.S. (eds) Mechanisms and Models in Toxicology. Archives of Toxicology, Supplement, vol 11. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72558-6_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-72558-6_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-17614-5
Online ISBN: 978-3-642-72558-6
eBook Packages: Springer Book Archive